These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17660651)

  • 21. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin-alpha dosage requirements in a provincial hemodialysis population: effect of switching from subcutaneous to intravenous administration.
    Raymond CB; Collins DM; Bernstein KN; Skwarchuk DE; Vercaigne LM
    Nephron Clin Pract; 2006; 102(3-4):c88-92. PubMed ID: 16282700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of iron loading on peripheral blood lymphocyte subsets and on circulating cytokine levels in iron-depleted hemodialysis patients receiving erythropoietin.
    Tsouchnikas I; Tsilipakou M; Daniilidis M; Kyriazis G; Pasadakis P; Parapanissiou E; Vargemezis V; Tsakiris D
    Nephron Clin Pract; 2007; 107(3):c97-102. PubMed ID: 17890877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
    Park L; Uhthoff T; Tierney M; Nadler S
    Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
    Daschner M; Mehls O; Schaefer F
    Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of the same dose of epoetin-beta intravenously and subcutaneously to patients with renal anaemia.
    Steffensen GK; Stergaard O
    Scand J Urol Nephrol; 2011 Dec; 45(6):461-9. PubMed ID: 21736448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of iron supply for erythropoietin therapy.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
    Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
    Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
    McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
    Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients.
    Messa P; Nicolini MA; Cesana B; Brezzi B; Zattera T; Magnasco A; Moroni G; Campise M
    Nephrol Dial Transplant; 2006 Feb; 21(2):431-6. PubMed ID: 16249199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
    Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
    Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous iron supplementation in children on hemodialysis.
    Leijn E; Monnens LA; Cornelissen EA
    J Nephrol; 2004; 17(3):423-6. PubMed ID: 15365964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of intravenous injection of iron saccharate in haemodialysis patients.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
    Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
    Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients.
    Wu CJ; Lin HC; Lee KF; Chuang CK; Chen YC; Chen HH
    Nephrology (Carlton); 2010 Feb; 15(1):42-7. PubMed ID: 20377770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attitude of physicians towards iron supplementation in hemodialysis patients treated with erythropoietin.
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2003; 14(2):134-44. PubMed ID: 18209438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous iron dextran treatment in predialysis patients with chronic renal failure.
    Dahdah K; Patrie JT; Bolton WK
    Am J Kidney Dis; 2000 Oct; 36(4):775-82. PubMed ID: 11007680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy.
    Sirken G; Kung SC; Raja R
    ASAIO J; 2003; 49(4):422-5. PubMed ID: 12918584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.